fbpx Skip to main content

Biocom California Newsletter Article

Bringing you the latest financial and strategic news from top leaders in life science.

RayzeBio Bags $105M in Series B; Gilead Acquires MYR GmbH; Salk Neuroscientists Receive $4.4 Million From NIH

  • 2020-12-10T20:00:00.000+0000
  • California
  • Author: Lauren Panetta

12/10/20 – Geron Corporation

Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS

12/10/20 – Twist Bioscience Corporation

Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments

12/10/20 – Lucence

Lucence Receives CLIA Certification for US Laboratory, Expands Access to Amplicon-Based Liquid Biopsy Tests

12/10/20 – TRACON Pharmaceuticals

TRACON Pharmaceuticals Announces Dosing Of First Patient In ENVASARC Pivotal Trial

12/10/20 – Denovo Biopharma

Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics

12/10/20 – Biocept

Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

12/10/20 – Gilead

Gilead Sciences to Acquire MYR GmbH

12/9/20 – Illumina

Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing

12/9/20 – Bolt Biotherapeutics

Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting

12/9/20 – Ultragenyx

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

12/9/20 – Sorrento Therapeutics

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients

12/9/20 – Mesa Biotech

Mesa Biotech Receives 510(k) Clearance and CLIA Waiver for Its Accula™ Strep A Molecular Point of Care Test

12/9/20 – Arcus Biosciences

Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

12/8/20 – RayzeBio

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer

12/8/20 – Regulus Therapeutics

Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity

12/8/20 – Ionis

Ionis Highlights Achievements, Commercial Strategy and Technology Advancements at Investor Day

12/8/20 – Turning Point Therapeutics

Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

12/8/20 – Boost Biomes

Boost Biomes Announces Extension of Series A with New Investor, Universal Materials Incubator

12/8/20 – Arena Pharmaceuticals

Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial

12/7/20 – Nektar

Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting

12/7/20 – Salk

Salk Neuroscientists Receive $4.4 Million From NIH Brain Initiative

12/7/20 – Arcturus

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

12/7/20 – Atara Biotherapeutics

Atara Biotherapeutics Announces Proposed Offering of Common Stock